Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing
Authors:
Open Access
- 3 October 2017
- journal article
- case report
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 18 (10) , 757-760
Abstract
Aggressive fibromatosis (AF) or desmoid tumors is an aggressive fibroblastic proliferation which is locally invasive but can not metastasize. The treatment of AF is challenging. Surgery was the main treatment modality for AF in the past, other strategies including radiotherapy, systemic therapies and wait-and-see policy. The use of non-steroidal anti-inflammatory drugs (NSAIDs) and targeted therapies has demonstrated good results. In the case report, a 39-year-old man presented with progressive chest wall pain. Computed tomography (CT) showed an approximately 46× 13 mm soft-tissue mass between the inside of the fifth and sixth rib on the right side. The entire mass was excised and an AF was confirmed based on histopathology. Four months after surgery, magnetic resonance imaging (MRI) showed a soft-tissue mass in surgical areas and biopsy confirmed local recurrence. Therefore, Tomotherapy was administered. However, two months later, an (18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography combined with CT (PET-CT) revealed the presence of an FDG-avid mass in the area of local recurrence. Genetic testing reported the presence of a p.T41A mutations on the CTNNB1 gene, which predicted that he is sensitive to the COX-2 inhibitor celecoxib. The tumor regressed rapidly after the application of celecoxib. Within the 20-month follow-up period, the patient showed remarkable regression without any signs and symptoms. Our case report provides further evidence for the efficacy of celecoxib in AF with CTNNB1 gene mutations. To our knowledge, this is the first report of AF treated with celecoxib under the guidance of the genetic testing. However, further studies are required.Keywords
This publication has 30 references indexed in Scilit:
- Desmoid Tumors: Clinical Features and Treatment Options for Advanced DiseaseThe Oncologist, 2011
- A nation‐wide study comparing sporadic and familial adenomatous polyposis‐related desmoid‐type fibromatosesInternational Journal of Cancer, 2010
- Celecoxib Inhibits β-Catenin-Dependent Survival of the Human Osteosarcoma MG-63 Cell LineJournal of International Medical Research, 2010
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upAnnals of Oncology, 2010
- Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot StudyJournal of Clinical Oncology, 2010
- Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon CancerCancer Research, 2008
- Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drugWorld Journal of Surgical Oncology, 2008
- Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive FibromatosisClinical Cancer Research, 2007
- Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapyNeurosurgical Focus, 2006
- Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)Oncogene, 1999